Zhao Chenxi, Liu Lu, Ge Ziruo, Wang Jingxia, Wang Ranran, Jiang Zhouling, Tian Di, Chen Zhihai
National Key Laboratory of Intelligent Tracking and Forecasting for infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
BMC Infect Dis. 2025 Aug 1;25(1):970. doi: 10.1186/s12879-025-11398-0.
The global circulation of SARS-CoV-2 has led to an increasing number of reinfections, raising concerns about their clinical and immune consequences. Understanding the differences in disease severity, vaccination impact, and immune response between primary infections and reinfections is essential for guiding public health strategies.
We conducted a retrospective cohort study of hospitalized COVID-19 patients at Beijing Ditan Hospital from January 2023 to June 2024. SARS-CoV-2 reinfection cases were matched 1:2 with primary infection cases using nearest neighbor propensity score matching (PSM) to balance age, sex, and comorbidities between the groups. Clinical characteristics, laboratory findings, serum antibody levels, lymphocyte subsets, and the impact of vaccination on disease severity were analyzed.
A total of 907 patients were included, comprising 821 with primary infection and 86 with reinfection. After matching, 131 cases remained in the primary infection group and 75 in the reinfection group. No significant differences were observed in disease severity, mortality, or most clinical symptoms. Trend analysis revealed that an increasing number of vaccine doses was significantly associated with a decreasing trend in severe disease in both the primary infection group (P = 0.0221) and the reinfection group (P = 0.0449). IgG levels were significantly higher in reinfected patients (P < 0.001), whereas IgM levels showed no significant difference (P = 0.474). Among patients with primary infection, severe cases exhibited lower T cell counts than non-severe cases (P < 0.001), but no significant differences in T cell subsets were observed between non-severe and severe reinfections.
The higher IgG levels in reinfected individuals suggest a robust immune memory response, while T cell depletion plays a crucial role in severe primary infections. Vaccination provided a protective effect against severe disease in both primary and reinfected individuals, with a significant decreasing trend in severe/critical cases as the number of vaccine doses increased.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的全球传播导致再感染病例数量不断增加,引发了人们对其临床和免疫后果的担忧。了解初次感染和再感染之间疾病严重程度、疫苗接种影响及免疫反应的差异对于指导公共卫生策略至关重要。
我们对2023年1月至2024年6月在北京地坛医院住院的新冠肺炎患者进行了一项回顾性队列研究。采用最近邻倾向评分匹配(PSM)方法,将SARS-CoV-2再感染病例与初次感染病例按1:2进行匹配,以平衡两组之间的年龄、性别和合并症。分析了临床特征、实验室检查结果、血清抗体水平、淋巴细胞亚群以及疫苗接种对疾病严重程度的影响。
共纳入907例患者,其中初次感染821例,再感染86例。匹配后,初次感染组剩余131例,再感染组剩余75例。在疾病严重程度、死亡率或大多数临床症状方面未观察到显著差异。趋势分析显示,在初次感染组(P = 0.0221)和再感染组(P = 0.0449)中,疫苗接种剂量增加均与重症疾病呈显著下降趋势相关。再感染患者的IgG水平显著更高(P < 0.001),而IgM水平无显著差异(P = 0.474)。在初次感染患者中,重症病例的T细胞计数低于非重症病例(P < 0.001),但非重症和重症再感染患者之间的T细胞亚群无显著差异。
再感染个体中较高的IgG水平表明存在强大的免疫记忆反应,而T细胞耗竭在严重初次感染中起关键作用。疫苗接种对初次感染和再感染个体的重症疾病均有保护作用,随着疫苗接种剂量的增加,重症/危重症病例呈显著下降趋势。